Key Highlights
● Ionis plunged on November 9 despite strong third-quarter Revenue growth.
● Revenue rose by more than half from a year earlier.
● The adjusted operating loss was smaller than analysts expected.
● The Tryngolza forecast was cut to about $50 million.
Two stories in one report
On paper, Ionis Pharmaceuticals (NASDAQ:IONS) had plenty to celebrate in its third-quarter report, released Monday, November 9, 2026. Revenue rose by more than half from a year earlier, and the company's adjusted operating loss was smaller than analysts had expected, according to news reports and the company's results filed with the Securities and Exchange Commission.
Yet the stock plunged. A mid-morning reading showed a dramatic drop, and an early-afternoon figure showed the shares still deeply in the red. The reason was a single line in the outlook: Ionis cut its 2026 sales forecast for Tryngolza to about $50 million, from $100 million to $110 million, citing a slower launch.
Why one drug outweighed the quarter
Investors value drug companies largely on what they expect future sales to be, not just on past results. Tryngolza, known scientifically as olezarsen, is a key part of Ionis's strategy to commercialize more of its own medicines rather than relying mainly on licensing deals with larger partners. That makes its launch a test of the company's ability to sell drugs on its own.
Halving the forecast raises questions about how quickly patients are being diagnosed, how doctors are adopting the treatment and how insurers are handling coverage. It also prompts investors to rethink longer-term estimates, which can outweigh a strong quarter.
The condition Tryngolza treats
Tryngolza is approved for familial chylomicronemia syndrome, a rare inherited disorder in which the body cannot properly break down certain fats, leading to extremely high triglyceride levels and a risk of acute pancreatitis. Because the condition is rare and often underdiagnosed, finding and treating eligible patients can take time, a common challenge for rare-disease launches.
Where the revenue growth came from
Ionis earns revenue from several sources, including its own products, royalties on medicines it has partnered and payments from collaboration deals. The strong top-line growth shows that the overall Business is expanding even as one product launch lags. Investors will want to see how sustainable that growth is and how much of it comes from recurring product sales versus one-time payments. Collaboration revenue can be lumpy, rising sharply in quarters when milestones are hit and falling back later, which is one reason markets often place more weight on product sales trends when judging a drugmaker's trajectory.
A day when most stocks rose
Ionis's slide was all the more noticeable given the backdrop. The Nasdaq Composite surged 673.71 points to 25,253.14, its best day since July 30, and the S&P 500 climbed 173.08 points to 7,549.94. Biotech, however, had several big losers on company news, including ImmunityBio (NASDAQ:IBRX), Faeth Therapeutics (NASDAQ:FTH) and Zura Bio (NASDAQ:ZURA).
Launch Trends Under the Microscope
Investors will watch Tryngolza's quarterly sales closely to see whether the launch picks up and whether Ionis can hit its lowered target. Management's explanation of the slowdown, and any steps to speed adoption, such as efforts to improve diagnosis rates, will be important.
Ionis's broader pipeline, including other medicines in late-stage development, could help shift the focus back to growth. Analysts may revise their estimates after the forecast cut. On the macro side, Tuesday's October Consumer Price Index is the last Inflation report before the Federal Reserve's December 8-9 meeting, where a rate hike is widely expected.






Please wait processing your request...